Cambridge, MANCT05655195Now EnrollingIRB Ready

Alzheimer Disease Clinical Trial in Cambridge, MA

Access cutting-edge alzheimer disease treatment through this clinical trial at a research site in Cambridge. Study-provided care at no cost to qualified participants.

Sponsored by Massachusetts Institute of Technology

Quick Self-Assessment

See if you qualify for this Cambridge location

Preparing your pre-screening questions…

Expert Care in Cambridge

Access alzheimer disease specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related alzheimer disease treatment provided free

Apply for This Cambridge Location

Check if you qualify for this alzheimer disease clinical trial in Cambridge, MA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Cambridge

    Convenient for MA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Cambridge site if eligible
  4. 4Begin participation

About This Alzheimer Disease Study in Cambridge

Alzheimer's disease (AD) is characterized by significant memory loss, toxic protein deposits amyloid and tau) in the brain, and changes in the gamma frequency band on EEG. The investigator's lab found that boosting gamma waves in AD mouse models using light and sound stimulation at 40Hz not only reduced amyloid and tau in the brain, but also improved memory. The investigators developed a light and sound device for humans that stimulates the brain at 40Hz that can be used safely at home. For the present study, 60 participants with mild Alzheimer's disease will be enrolled and will use this light and sound device at-home daily for 6-months. Investigators will measure changes in brain waves with EEG, blood biomarkers, the microbiome via fecal samples, functional and structural MRI scans, memory and cognitive testing, and questionnaires at 3 in-person visits throughout the study. After the 6-month time point, participants will have the option of continuing in the study for at least one year and completing yearly study visits. This study will provide critical insight into extended therapy involving non-invasive 40Hz sensory stimulation as a possible therapeutic strategy for mild to moderate Alzheimer's disease.

Sponsor: Massachusetts Institute of Technology

Who Can Participate

Inclusion Criteria

Subjects may be enrolled into the study if they meet all of the following criteria:
Subject is between the ages of 65 - 100.
Subject must have mild Alzheimer's disease with a Mini Mental State Exam (MMSE) score of 19-26.
Subject is willing to sign informed consent document.
If subject is deemed to not have capacity to sign the informed consent, he/she will need a legally authorized representative to provide surrogate consent.
Able to complete the 1st month of at home stimulation at their primary residence. If subjects plan to spend more than 1 week away from their primary residence during the trial, their inclusion must be assessed by the research team.

Exclusion Criteria

Subjects who meet any of the following conditions will not be enrolled in the study:
Subjects who do not have healthcare.
Subjects who are currently taking amyloid reducing therapy.
Subjects who have \> 4 cerebral microbleeds or 1 macrobleed in their brain
Active treatment on a dosage of one or more psychiatric agents (e.g. antidepressants, antipsychotics, etc) for LESS THAN three months (a stable dose for greater than or equal to three months is ok).
Subjects who are actively diagnosed with cancer and undergoing cancer-related treatments
Subjects who are being treated with N-methyl-D-aspartate (NMDA) receptor antagonists (eg. Memantine).
Subjects on medications that lower seizure threshold such as wellbutrin, ciprofloxacin, levofloxacin, etc.
Subjects with history of seizure or epilepsy
Subjects with clinically significant suicide risk and/or suicide attempt in the past 1 year.
Subjects with behavioral problems such as aggression/agitation/impulsivity that might interfere with their ability to comply with protocol.
Subjects with untreated or unstable depression
Active treatment with one or more anti-epileptic agent.
Subjects who have had a stroke within the past 24 months.
Subjects who have had eye surgery in the last 3 months or are scheduled to have eye surgery in the next 6 months (during the study)
Subjects diagnosed with migraine headache.
Subjects who have an active implantable medical device including but not limited to implantable cardioverter defibrillator (ICD), deep brain stimulator (DBS), cardiac pacemaker, and/or sacral nerve stimulator.
Subjects who have profound hearing or visual impairment.
Subjects who have a life expectancy of less than 2 years.
Subjects who are pregnant.
Current or past history of any neurological disorder other than dementia, such as epilepsy, stroke, progressive neurologic disease (e.g. multiple sclerosis) or intracranial brain lesions; and history of previous neurosurgery or head trauma that resulted in residual neurologic impairment.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Cambridge?

Yes, this clinical trial (NCT05655195) has an active research site in Cambridge, MA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Alzheimer Disease Treatment Options in Cambridge, MA

If you're searching for alzheimer disease treatment options in Cambridge, MA, this clinical trial (NCT05655195) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Cambridge research site is actively enrolling participants for this clinical trial. You'll receive care from experienced alzheimer disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all alzheimer disease clinical trials near you to find additional studies recruiting in your area.

More Alzheimers Disease Trials in Cambridge, MA

See all alzheimers disease clinical trials recruiting in Cambridge — not just this study.

Browse Alzheimers Disease Trials in Cambridge →

Browse More Trials by Condition

Alzheimers Disease TrialsAnkylosing Spondylitis TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Cambridge?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Cambridge, MA